Reversing anticoagulation

Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Kramkowski K, Mogielnicki A, Nowakowska M and Buczko W (2012) Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis Eur J Pharmacol 686(1-3):81-9

Kamiński K, Kałaska B, Koczurkiewicz P, Michalik M, Szczubiałka K, Mogielnicki A, Buczko W, Nowakowska M (2014) New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. MedChemComm. 5(4):489-495

Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalinska K, Bereta J, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2015) Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS One. 17;10(3):e0119486

Sokolowska E, Kalaska B,  Kaminski K, Lewandowska A, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2016) The toxicokinetic profile of Dex40-GTMAC3 – a novel polysaccharide candidate for reversal of unfractionated heparin. Front Pharmacol. 7:60. doi:10.3389/fphar.2016.00060

Kalaska B,  Kaminski K, Miklosz J, Yusa SI, Sokolowska E, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2016) Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice. Transl Res. S1931-5244(16)30102-5. doi: 10.1016/j.trsl.2016.06.009

Innovations for licencing:

1. The use of dextran derivatives in preventing or treating anemia, WO 2013157967 A1: New therapeutic use of cationic derivative of dextran is described here in detail.

2. The use of new block polymers for neutralization of unfractionated and low-molecular-weight heparins is described here in detail..

Please do not hesitate to contact me directly or Centrum Transferu Technologii CITTRU of Jagiellonian University, Cracow, Poland for possible licensing.

Angiotensins and Thrombosis

Mogielnicki et al Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005

Kaminska et al . Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol  2005

Kramkowski et al. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006

Kramkowski et al. Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. J Physiol Pharmacol 2010

Mogielnicki et al. Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. J Renin Angiotensin Aldosterone Syst 2013

Cardiovascular effects of MNA

Mechanism of antithrombotic action

Mogielnicki et al. N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats. J Physiol Pharmacol 2007

Chlopicki et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol 2007

Mogielnicki et al. N-methylnicotinamide failed to induce endothelial prostacyclin release in perfused rat hindquarters. Pharmacol Rep 2008

Pietrzak et al. Nicotinamide and its metabolite N-methylnicotinamide increase skin vascular permeability in rats. Clin Exp Dermatol  2009

Asthma and fibrinolysis

Kucharewicz et al. Plasmin system regulation in an ovalbumin-induced rat model of asthma. Int Arch Allergy Immunol 2008

Full list of my publications